Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA reports medical-technology developments tied to the Genio system, its patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. Company news commonly covers financial and operating results, U.S. commercialization activity, regulatory status, manufacturing capacity, reimbursement references, investor conference participation, and the development and commercialization of OSA treatment alternatives.
Nyxoah also publishes regulated information for its Euronext Brussels and Nasdaq securities, including transparency notifications, shareholder-meeting materials, voting-right disclosures, and bond-related capital-structure notices.
Nyxoah (Nasdaq:NYXH) reported preliminary, unaudited Q2 2026 results, with global net revenue expected at €7.7 million, up 21% sequentially, and U.S. revenue at €5.2 million, up 22%.
The company secured $110 million in Q2 financing, ended June 30 with about €97.8 million in cash and financial assets, and reaffirmed 2026 revenue guidance of €36–40 million. CMS proposed 2027 reimbursement increases for the Genio procedure of 12% for hospital outpatient and 15% for ASC settings.
Nyxoah (Nasdaq: NYXH) reported updated share capital and voting rights as of June 30, 2026, after issuing 146,531 new shares from exercised restricted share units.
Share capital is EUR 7,075,152.31 with 100,072,815 ordinary shares and the same number of voting rights.
Nyxoah (NASDAQ:NYXH) reported two transparency notifications under Belgian disclosure rules after changes in major shareholdings as of June 10, 2026.
Entities controlled by Orin Hirchman now hold 14,534,880 voting rights, or 14.55% of Nyxoah’s 99,926,284 shares. Resmed passively moved below the 3% threshold and now holds 1,943,828 voting rights, or 1.95%.
Nyxoah (Nasdaq: NYXH) will host an Investor and Analyst Day in New York on July 8, 2026, from 10:00 AM to 12:30 PM ET at Bank of America Tower.
The event will cover U.S. Genio launch momentum, OSA market dynamics, reimbursement, and the company’s path to profitability, and will be accessible via live webcast and replay.
Nyxoah (Nasdaq:Euronext: NYXH) convenes an extraordinary shareholders’ meeting on July 9, 2026 at 2:00 p.m. CET at its registered office.
Key agenda items include renewing the board’s authorization to increase share capital for five years and granting powers to the notary. Attendance requires registration by the June 25, 2026 record date and confirmation by July 3, 2026. Shareholders may vote by mail or proxy and follow the meeting via non-voting videoconference.
Nyxoah (Nasdaq/Euronext: NYXH) published multiple transparency notifications on recent shareholding changes as required under Belgian law.
Notifications cover Robert Taub/Robelga (14.50% including warrants), Pierre‑Edouard Stérin/B.A.D. 21 (7.23%), Cochlear Limited (5.85%), Gilde Healthcare (below 3%), and Bank of America around the 3% threshold via voting rights and financial instruments.
Nyxoah (Nasdaq: NYXH) received $15 million (€13.8 million) from the second tranche of its European Investment Bank loan facility, described as non-dilutive debt funding.
This drawdown brings total new capital raised in June 2026 to about $110 million, supporting the U.S. commercial launch of Genio, R&D, and manufacturing scale-up.
Nyxoah (Nasdaq: NYXH) announced that its Genio® hypoglossal nerve stimulation therapy for Obstructive Sleep Apnea won the Prix Galien UK 2026 Award for Best Medical Technology in London.
The award follows FDA approval, U.S. commercial launch, new financing for U.S. expansion, and growing international adoption of Genio.
Nyxoah (Nasdaq: NYXH) reported updated share and voting rights information following the issuance of 55,232,558 new shares linked to its underwritten public offering in the United States.
The company now has share capital of EUR 7,073,687 and 99,926,284 ordinary shares, all carrying voting rights.
Nyxoah (Nasdaq: NYXH) announced $110 million in aggregate financings to support the U.S. commercial launch of its Genio system for obstructive sleep apnea.
The company completed a $95 million equity financing and expects a $15 million second tranche from its European Investment Bank loan by end of June 2026, backing an accelerated U.S. commercialization with 40 sales reps already in place.